Trial Outcomes & Findings for Isthmus Ablation With Gold Electrode for Treatment of Atrial Flutter (AURUM 8) (NCT NCT00326001)

NCT ID: NCT00326001

Last Updated: 2010-02-18

Results Overview

Cumulative amount of time current is flowing through the catheter tip. The current (in the radiofrequency range) is applied to ablate the cavotricuspid isthmus in the right atrium.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

463 participants

Primary outcome timeframe

ablation procedure

Results posted on

2010-02-18

Participant Flow

A total of 463 patients were enrolled in the AURUM 8 study from June 2004 to March 2007 in 19 clinical centers in Germany and the Czech Republic.

No exclusion before assignment

Participant milestones

Participant milestones
Measure
Gold Tip Catheter
Patients allocated to be ablated by 8-mm gold tip catheter
Pt-Ir Tip Catheter
Patients allocated to be ablated by 8-mm Platinum-Iridium tip catheter
Overall Study
STARTED
236
227
Overall Study
COMPLETED
229
219
Overall Study
NOT COMPLETED
7
8

Reasons for withdrawal

Reasons for withdrawal
Measure
Gold Tip Catheter
Patients allocated to be ablated by 8-mm gold tip catheter
Pt-Ir Tip Catheter
Patients allocated to be ablated by 8-mm Platinum-Iridium tip catheter
Overall Study
Adverse Event
4
5
Overall Study
Physician Decision
3
3

Baseline Characteristics

Isthmus Ablation With Gold Electrode for Treatment of Atrial Flutter (AURUM 8)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Gold Tip Catheter
n=236 Participants
Patients allocated to be ablated by 8-mm gold tip catheter
Pt-Ir Tip Catheter
n=227 Participants
Patients allocated to be ablated by 8-mm Platinum-Iridium tip catheter
Total
n=463 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Age, Categorical
Between 18 and 65 years
97 Participants
n=99 Participants
92 Participants
n=107 Participants
189 Participants
n=206 Participants
Age, Categorical
>=65 years
139 Participants
n=99 Participants
135 Participants
n=107 Participants
274 Participants
n=206 Participants
Age Continuous
66 years
STANDARD_DEVIATION 10 • n=99 Participants
66 years
STANDARD_DEVIATION 11 • n=107 Participants
66 years
STANDARD_DEVIATION 11 • n=206 Participants
Sex: Female, Male
Female
45 Participants
n=99 Participants
35 Participants
n=107 Participants
80 Participants
n=206 Participants
Sex: Female, Male
Male
191 Participants
n=99 Participants
192 Participants
n=107 Participants
383 Participants
n=206 Participants
Region of Enrollment
Czech Republic
9 participants
n=99 Participants
8 participants
n=107 Participants
17 participants
n=206 Participants
Region of Enrollment
Germany
227 participants
n=99 Participants
219 participants
n=107 Participants
446 participants
n=206 Participants

PRIMARY outcome

Timeframe: ablation procedure

Population: Per protocol

Cumulative amount of time current is flowing through the catheter tip. The current (in the radiofrequency range) is applied to ablate the cavotricuspid isthmus in the right atrium.

Outcome measures

Outcome measures
Measure
Gold Tip Catheter
n=229 Participants
Patients allocated to be ablated by 8-mm gold tip catheter
Pt-Ir Tip Catheter
n=219 Participants
Patients allocated to be ablated by 8-mm Platinum-Iridium tip catheter
Duration of Energy Application
10.2 minute
Standard Deviation 6.9
10.9 minute
Standard Deviation 6.9

SECONDARY outcome

Timeframe: ablation procedure

Population: per protocol

Delivery of radiofrequency current was repeated until a cavotricuspid isthmus (CTI) conduction block was detected. The final bidirectional CTI block test (well documented in the literature) was performed 20 minutes after the last radiofrequency current delivery to assess ablation success (Y/N). Positive final bidirectional cavotricuspid isthmus condution block test means "ablation successful". Negative final bidirectional cavotricuspid isthmus condution block test means "ablation unsuccessful"; ablation should be continued until success or terminated and classified as unsuccess.

Outcome measures

Outcome measures
Measure
Gold Tip Catheter
n=229 Participants
Patients allocated to be ablated by 8-mm gold tip catheter
Pt-Ir Tip Catheter
n=219 Participants
Patients allocated to be ablated by 8-mm Platinum-Iridium tip catheter
Ablation Success With the First Catheter
216 Patients
195 Patients

SECONDARY outcome

Timeframe: 6 months after ablation

Population: per protocol

No recurrence of atrial flutter after ablation

Outcome measures

Outcome measures
Measure
Gold Tip Catheter
n=229 Participants
Patients allocated to be ablated by 8-mm gold tip catheter
Pt-Ir Tip Catheter
n=219 Participants
Patients allocated to be ablated by 8-mm Platinum-Iridium tip catheter
Number of Patients With Long-term Treatment Success
225 Patients
213 Patients

SECONDARY outcome

Timeframe: ablation procedure

Population: per protocol

Char or coagulum formation on the catheter tip

Outcome measures

Outcome measures
Measure
Gold Tip Catheter
n=229 Participants
Patients allocated to be ablated by 8-mm gold tip catheter
Pt-Ir Tip Catheter
n=219 Participants
Patients allocated to be ablated by 8-mm Platinum-Iridium tip catheter
Number of Patients With Charred Catheter Tips
11 Patients
83 Patients

Adverse Events

Gold Tip Catheter

Serious events: 20 serious events
Other events: 0 other events
Deaths: 0 deaths

Pt-Ir Tip Catheter

Serious events: 12 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Gold Tip Catheter
n=229 participants at risk
Patients allocated to be ablated by 8-mm gold tip catheter
Pt-Ir Tip Catheter
n=219 participants at risk
Patients allocated to be ablated by 8-mm Platinum-Iridium tip catheter
General disorders
Death
0.87%
2/229 • Number of events 2
0.46%
1/219 • Number of events 1
General disorders
Hospitalization
7.9%
18/229 • Number of events 18
5.5%
12/219 • Number of events 12

Other adverse events

Adverse event data not reported

Additional Information

Dejan Danilovic

Biotronik GmbH&Co. KG, Berlin, Germany

Phone: +49 9131 8924 7832

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place